Macrophage-Induced Lymphangiogenesis and Metastasis following Paclitaxel Chemotherapy Is Regulated by VEGFR3

Cell Reports

Volumn 17, Issue 5, 2016, Pages 1344-1356

  Alishekevitz, Dror ^a   Gingis Velitski, Svetlana ^a   Kaidar Person, Orit ^b   Gutter Kapon, Lilach ^a   Scherer, Sandra D ^c,d   Raviv, Ziv ^a   Merquiol, Emmanuelle ^e   Ben Nun, Yael ^e   Miller, Valeria ^a   Rachman Tzemah, Chen ^a   Timaner, Michael ^a   Mumblat, Yelena ^a   Ilan, Neta ^a   Loven, David ^f   Hershkovitz, Dov ^g   Satchi Fainaro, Ronit ^h   Blum, Galia ^e   P Sleeman, Jonathan ^c,d   Vlodavsky, Israel ^a   Shaked, Yuval ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Division of Oncology   (Israel)

^c KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^f HAEMEK MEDICAL CENTER   (Israel)

^g Tel Aviv University ^*  (Israel)

^h TEL AVIV UNIVERSITY   (Israel)

Author keywords

chemotherapy; host response; lymphangiogenesis; macrophages; metastatis; VEGF C

Indexed keywords

CATHEPSIN; CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HEPARANASE; OXALIPLATIN; PACLITAXEL; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3; BETA GLUCURONIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CELL ACTIVATION; CELL ACTIVITY; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; LYMPH VESSEL; METABOLISM; METASTASIS; PATHOLOGY; PHENOTYPE; TUMOR CELL LINE;

ANIMALS; CATHEPSINS; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOTHELIAL CELLS; FEMALE; GLUCURONIDASE; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; MACROPHAGES; MICE, INBRED BALB C; NEOPLASM METASTASIS; PACLITAXEL; PHENOTYPE; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84994759902     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.09.083     Document Type: Article

References (44)

1. Alishekevitz, D., Bril, R., Loven, D., Miller, V., Voloshin, T., Gingis-Velistki, S., Fremder, E., Scherer, S.J., Shaked, Y., Differential therapeutic effects of anti-VEGF-A antibody in different tumor models: implications for choosing appropriate tumor models for drug testing. Mol. Cancer Ther. 13 (2014), 202–213.
2. Alitalo, K., Carmeliet, P., Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1 (2002), 219–227.
3. Alitalo, A., Detmar, M., Interaction of tumor cells and lymphatic vessels in cancer progression. Oncogene 31 (2012), 4499–4508.
4. Arvatz, G., Shafat, I., Levy-Adam, F., Ilan, N., Vlodavsky, I., The heparanase system and tumor metastasis: is heparanase the seed and soil?. Cancer Metastasis Rev. 30 (2011), 253–268.
5. Bar-Ner, M., Kramer, M.D., Schirrmacher, V., Ishai-Michaeli, R., Fuks, Z., Vlodavsky, I., Sequential degradation of heparan sulfate in the subendothelial extracellular matrix by highly metastatic lymphoma cells. Int. J. Cancer 35 (1985), 483–491.
6. Chung, E.S., Chauhan, S.K., Jin, Y., Nakao, S., Hafezi-Moghadam, A., van Rooijen, N., Zhang, Q., Chen, L., Dana, R., Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands. Am. J. Pathol. 175 (2009), 1984–1992.
7. Cohen-Kaplan, V., Naroditsky, I., Zetser, A., Ilan, N., Vlodavsky, I., Doweck, I., Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int. J. Cancer 123 (2008), 2566–2573.
8. De Palma, M., Lewis, C.E., Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 23 (2013), 277–286.
9. Fisher, E.R., Redmond, C., Fisher, B., Pathologic findings from the National Surgical Adjuvant Breast Project. VIII. Relationship of chemotherapeutic responsiveness to tumor differentiation. Cancer 51 (1983), 181–191.
10. Gingis-Velitski, S., Loven, D., Benayoun, L., Munster, M., Bril, R., Voloshin, T., Alishekevitz, D., Bertolini, F., Shaked, Y., Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice. Cancer Res. 71 (2011), 6986–6996.
11. Hagemann, T., Biswas, S.K., Lawrence, T., Sica, A., Lewis, C.E., Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB. Blood 113 (2009), 3139–3146.
12. Hoshida, T., Isaka, N., Hagendoorn, J., di Tomaso, E., Chen, Y.L., Pytowski, B., Fukumura, D., Padera, T.P., Jain, R.K., Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res. 66 (2006), 8065–8075.
13. Hughes, R., Qian, B.Z., Rowan, C., Muthana, M., Keklikoglou, I., Olson, O.C., Tazzyman, S., Danson, S., Addison, C., Clemons, M., et al. Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. Cancer Res. 75 (2015), 3479–3491.
14. Jung, J.I., Cho, H.J., Jung, Y.J., Kwon, S.H., Her, S., Choi, S.S., Shin, S.H., Lee, K.W., Park, J.H., High-fat diet-induced obesity increases lymphangiogenesis and lymph node metastasis in the B16F10 melanoma allograft model: roles of adipocytes and M2-macrophages. Int. J. Cancer 136 (2015), 258–270.
15. Kim, K.E., Koh, Y.J., Jeon, B.H., Jang, C., Han, J., Kataru, R.P., Schwendener, R.A., Kim, J.M., Koh, G.Y., Role of CD11b+ macrophages in intraperitoneal lipopolysaccharide-induced aberrant lymphangiogenesis and lymphatic function in the diaphragm. Am. J. Pathol. 175 (2009), 1733–1745.
16. Kirkin, V., Mazitschek, R., Krishnan, J., Steffen, A., Waltenberger, J., Pepper, M.S., Giannis, A., Sleeman, J.P., Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2. Eur. J. Biochem. 268 (2001), 5530–5540.
17. Kukk, E., Lymboussaki, A., Taira, S., Kaipainen, A., Jeltsch, M., Joukov, V., Alitalo, K., VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 122 (1996), 3829–3837.
18. Laakkonen, P., Waltari, M., Holopainen, T., Takahashi, T., Pytowski, B., Steiner, P., Hicklin, D., Persaud, K., Tonra, J.R., Witte, L., Alitalo, K., Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res. 67 (2007), 593–599.
19. Mäkinen, T., Jussila, L., Veikkola, T., Karpanen, T., Kettunen, M.I., Pulkkanen, K.J., Kauppinen, R., Jackson, D.G., Kubo, H., Nishikawa, S., et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat. Med. 7 (2001), 199–205.
20. Mandriota, S.J., Jussila, L., Jeltsch, M., Compagni, A., Baetens, D., Prevo, R., Banerji, S., Huarte, J., Montesano, R., Jackson, D.G., et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 20 (2001), 672–682.
21. Matsumoto, M., Roufail, S., Inder, R., Caesar, C., Karnezis, T., Shayan, R., Farnsworth, R.H., Sato, T., Achen, M.G., Mann, G.B., Stacker, S.A., Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis. Clin. Exp. Metastasis 30 (2013), 819–832.
22. Munoz, R., Man, S., Shaked, Y., Lee, C.R., Wong, J., Francia, G., Kerbel, R.S., Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res. 66 (2006), 3386–3391.
23. Navab, R., Mort, J.S., Brodt, P., Inhibition of carcinoma cell invasion and liver metastases formation by the cysteine proteinase inhibitor E-64. Clin. Exp. Metastasis 15 (1997), 121–129.
24. Ni, X., Zhao, Y., Ma, J., Xia, T., Liu, X., Ding, Q., Zha, X., Wang, S., Hypoxia-induced factor-1 alpha upregulates vascular endothelial growth factor C to promote lymphangiogenesis and angiogenesis in breast cancer patients. J. Biomed. Res. 27 (2013), 478–485.
25. Schoppmann, S.F., Bayer, G., Aumayr, K., Taucher, S., Geleff, S., Rudas, M., Kubista, E., Hausmaninger, H., Samonigg, H., Gnant, M., et al., Austrian Breast and Colorectal Cancer Study Group. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann. Surg. 240 (2004), 306–312.
26. Shafat, I., Barak, A.B., Postovsky, S., Elhasid, R., Ilan, N., Vlodavsky, I., Arush, M.W., Heparanase levels are elevated in the plasma of pediatric cancer patients and correlate with response to anticancer treatment. Neoplasia 9 (2007), 909–916.
27. Shaked, Y., Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects. Nat. Rev. Clin. Oncol. 13 (2016), 611–626.
28. Shaked, Y., Bertolini, F., Man, S., Rogers, M.S., Cervi, D., Foutz, T., Rawn, K., Voskas, D., Dumont, D.J., Ben-David, Y., et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7 (2005), 101–111.
29. Shaked, Y., Henke, E., Roodhart, J.M., Mancuso, P., Langenberg, M.H., Colleoni, M., Daenen, L.G., Man, S., Xu, P., Emmenegger, U., et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14 (2008), 263–273.
30. Shaked, Y., Tang, T., Woloszynek, J., Daenen, L.G., Man, S., Xu, P., Cai, S.R., Arbeit, J.M., Voest, E.E., Chaplin, D.J., et al. Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res. 69 (2009), 7524–7528.
31. Shi, V.Y., Bao, L., Chan, L.S., Inflammation-driven dermal lymphangiogenesis in atopic dermatitis is associated with CD11b+ macrophage recruitment and VEGF-C up-regulation in the IL-4-transgenic mouse model. Microcirculation 19 (2012), 567–579.
32. Shree, T., Olson, O.C., Elie, B.T., Kester, J.C., Garfall, A.L., Simpson, K., Bell-McGuinn, K.M., Zabor, E.C., Brogi, E., Joyce, J.A., Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 25 (2011), 2465–2479.
33. Skobe, M., Hawighorst, T., Jackson, D.G., Prevo, R., Janes, L., Velasco, P., Riccardi, L., Alitalo, K., Claffey, K., Detmar, M., Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7 (2001), 192–198.
34. Sleeman, J.P., Thiele, W., Tumor metastasis and the lymphatic vasculature. Int. J. Cancer 125 (2009), 2747–2756.
35. Stacker, S.A., Achen, M.G., Jussila, L., Baldwin, M.E., Alitalo, K., Lymphangiogenesis and cancer metastasis. Nat. Rev. Cancer 2 (2002), 573–583.
36. Timaner, M., Bril, R., Kaidar-Person, O., Rachman-Tzemah, C., Alishekevitz, D., Kotsofruk, R., Miller, V., Nevelsky, A., Daniel, S., Raviv, Z., et al. Dequalinium blocks macrophage-induced metastasis following local radiation. Oncotarget 6 (2015), 27537–27554.
37. Varshavsky, A., Kessler, O., Abramovitch, S., Kigel, B., Zaffryar, S., Akiri, G., Neufeld, G., Semaphorin-3B is an angiogenesis inhibitor that is inactivated by furin-like pro-protein convertases. Cancer Res. 68 (2008), 6922–6931.
38. Veikkola, T., Jussila, L., Makinen, T., Karpanen, T., Jeltsch, M., Petrova, T.V., Kubo, H., Thurston, G., McDonald, D.M., Achen, M.G., et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 20 (2001), 1223–1231.
39. Voloshin, T., Alishekevitz, D., Kaneti, L., Miller, V., Isakov, E., Kaplanov, I., Voronov, E., Fremder, E., Benhar, M., Machluf, M., et al. Blocking IL-1beta pathway following paclitaxel chemotherapy slightly inhibits primary tumor growth but promotes spontaneous metastasis. Mol. Cancer Ther. 14 (2015), 1385–1394.
40. Wang, E.S., Teruya-Feldstein, J., Wu, Y., Zhu, Z., Hicklin, D.J., Moore, M.A., Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 104 (2004), 2893–2902.
41. Watari, K., Shibata, T., Kawahara, A., Sata, K., Nabeshima, H., Shinoda, A., Abe, H., Azuma, K., Murakami, Y., Izumi, H., et al. Tumor-derived interleukin-1 promotes lymphangiogenesis and lymph node metastasis through M2-type macrophages. PLoS ONE, 9, 2014, e99568.
42. Welford, A.F., Biziato, D., Coffelt, S.B., Nucera, S., Fisher, M., Pucci, F., Di Serio, C., Naldini, L., De Palma, M., Tozer, G.M., Lewis, C.E., TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J. Clin. Invest. 121 (2011), 1969–1973.
43. Zcharia, E., Jia, J., Zhang, X., Baraz, L., Lindahl, U., Peretz, T., Vlodavsky, I., Li, J.P., Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS ONE, 4, 2009, e5181.
44. Zhang, Y., Lu, Y., Ma, L., Cao, X., Xiao, J., Chen, J., Jiao, S., Gao, Y., Liu, C., Duan, Z., et al. Activation of vascular endothelial growth factor receptor-3 in macrophages restrains TLR4-NF-κB signaling and protects against endotoxin shock. Immunity 40 (2014), 501–514.